Synapse Global Theranostics Launches to Bridge Precision Medicine Gap in Latin America
New Joint Venture by Nucleotron MIT, bioaccess®, and amavita Heart and Vascular Health® to Build Turnkey Theranostic Centers of Excellence, Targeting Region’s USD 1 Billion Nuclear Medicine Market
MIAMI, FL – August 10, 2025 – Three leading healthcare organizations today announced the formation of Synapse Global Theranostics Inc., a new company created to deliver critical infrastructure for precision medicine to Latin America. The joint venture unites the radiopharmaceutical and operational expertise of Nucleotron Molecular Imaging & Technology, LLC (Nucleotron MIT), the Latin American market access and clinical trial leadership of IMH ASSETS CORP (bioaccess®), and the pioneering cardiovascular research and clinical excellence of Amavita Holding LLC (amavita Heart and Vascular Health®).
Synapse Global Theranostics is being established to address the unmet need for advanced molecular imaging and targeted therapies across Latin America. The company will deploy a proven Management Services Organization (MSO) model to establish a network of world-class theranostic centers, enabling local healthcare systems to access next-generation diagnostics and treatments for the first time. The venture is positioned to capture a significant share of the Latin American nuclear medicine market, which was valued at over USD 1 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 10.4% through 2030.
The Opportunity: Solving a Critical Healthcare Infrastructure Challenge
Precision medicine, which leverages patient-specific data to tailor treatments, represents one of the most significant advances in modern healthcare. However, its adoption in Latin America has been hampered by fundamental challenges, including fragmented clinical research environments, a lack of trained personnel, and limited access to the essential radiopharmaceuticals required for theranostic procedures. Theranostics, a field that combines diagnostic imaging with targeted therapy, is a cornerstone of precision medicine, particularly in oncology and cardiology.
Synapse Global Theranostics was purpose-built to solve these challenges. The company provides a comprehensive, turnkey solution that empowers local hospitals and research centers to build and operate self-sustaining theranostic programs. This integrated model combines:
On-Site Radiopharmaceutical Production: Leveraging exclusive rights to the ultra-compact IONETIX ION-12SC cyclotron, enabling local, reliable production of critical isotopes like N-13 Amonia for advanced cardiac PET imaging and other tracers.
Proven Operational Blueprint: Implementing a U.S.-proven MSO model based on the success of CIRA Health, a Nucleotron MIT affiliate, to manage everything from site planning and quality assurance to technology transfer and personnel training.
Expert Clinical and Regulatory Support: Providing end-to-end management of clinical trial workflows and navigating complex regulatory pathways to accelerate research and the adoption of new therapies.
"Synapse is not simply a technology vendor; we are an infrastructure and enablement partner," said Alberto Gil de Montes, BS, MS, CNMT for Nucleotron MIT. "Our model, proven in the U.S., de-risks the entire process for Latin American institutions. By providing the technology, the operational know-how, and the capital strategy, we are making it possible for our partners to leapfrog legacy systems and become regional leaders in precision medicine. This is about building sustainable capability, not just selling equipment."
A Synergistic Alliance of Industry Leaders
The formation of Synapse Global Theranostics Inc. was formalized in a shareholders' agreement effective July 23, 2025. The company, a Delaware corporation, is owned by Nucleotron MIT, bioaccess®, and amavita Heart and Vascular Health®. The venture capitalizes on the unique and complementary strengths of its founding partners.
Nucleotron MIT (Nucleotron Molecular Imaging & Technology, LLC): A subsidiary of CIRA Health, Nucleotron brings extensive experience in molecular imaging and the successful implementation of radiopharmaceutical production centers and clinical trial imaging networks.
bioaccess® (IMH ASSETS CORP): A leader in accelerating clinical research in Latin America, bioaccess® contributes over 15 years of expertise in first-in-human trials, clinical trial management, and navigating the region's regulatory landscape.
amavita Heart and Vascular Health® (AMAVITA HOLDING LLC): A premier cardiovascular care center founded by Dr. Pedro Martinez-Clark, MD, FACC, amavita provides deep clinical expertise, a track record of pioneering research in cardiac imaging, and serves as the foundational model for the venture's clinical centers of excellence.
"Our mission at bioaccess® has always been to connect Latin America to the global clinical research ecosystem. Synapse is the ultimate expression of that mission," said Julio G. Martinez-Clark, CEO of bioaccess®. "By creating the infrastructure for advanced theranostics, we are improving patient access to cutting-edge care and making Latin America a premier destination for global pharmaceutical and Medtech sponsors seeking to conduct early-phase clinical trials. This will accelerate the availability of new life-saving therapies for the entire region."
Initial Focus: Addressing the Cardiovascular Health Crisis
Synapse Global Theranostics will initially focus its platform on one of Latin America's most pressing health challenges: cardiovascular disease. Hypertension is the leading risk factor for CVD in the region, contributing to over two million deaths annually, with one million of those occurring before the age of 70.
The venture will deploy advanced cardiac Positron Emission Tomography (PET) imaging, a powerful diagnostic tool that can detect heart disease with superior accuracy, often years before symptoms appear. This capability is critical for early intervention and personalized treatment planning. Dr. Pedro Martinez-Clark, a Harvard-trained interventional cardiologist who will serve as Chief Medical Officer for Synapse Global Theranostics, will lead this initiative.
"This partnership represents a transformative moment for cardiology in Latin America," said Dr. Martinez-Clark. "For too long, we have been forced to diagnose heart disease after significant damage has already occurred. With the tools Synapse is bringing to the region—like advanced PET myocardial perfusion imaging using tracers such as flurpiridaz F-18—we can shift the paradigm to proactive, predictive, and personalized care. By combining this powerful imaging with AI-assisted diagnostics like POCAD™, we can provide clinicians with the precise information they need to save lives."
About Synapse Global Theranostics Inc.: Synapse Global Theranostics Inc. is a Delaware corporation formed to build and manage a network of advanced molecular imaging and theranostics centers of excellence throughout Latin America. By providing a turnkey infrastructure solution that includes on-site radiopharmaceutical production, a proven operational MSO model, and expert clinical research support, Synapse empowers local healthcare institutions to provide world-class precision medicine. The company's mission is to democratize access to life-saving diagnostic and therapeutic technologies for patients across the region. For more information, visit synapseglobaltheranostics.com.
About Nucleotron Molecular Imaging & Technology, LLC: Nucleotron MIT, a CIRA Health spinoff, is a leader in developing and managing molecular imaging and radiopharmaceutical production facilities. The company has supported over 15 radiopharmaceutical trials and provides the operational blueprint for building successful, integrated theranostic programs.
About bioaccess® bioaccess® (IMH ASSETS CORP) is a contract research organization (CRO) and market access specialist that accelerates the development of innovative medical technologies in Latin America. With over 15 years of experience, bioaccess® provides comprehensive clinical trial management, regulatory consulting, and market entry services for pharmaceutical and Medtech companies.
About amavita Heart and Vascular Health®: amavita Heart and Vascular Health® (AMAVITA HOLDING LLC) is a premier cardiovascular center in South Florida founded by Dr. Pedro Martinez-Clark, MD, FACC. The center is a hub for minimally invasive cardiac care, clinical research, and medical innovation, with pioneering work in AI-assisted cardiac diagnosis and advanced cardiac imaging.
